Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

HNRNPH1-dependent splicing of a fusion oncogene reveals a targetable RNA G-quadruplex interaction.

Neckles C, Boer RE, Aboreden N, Cross AM, Walker RL, Kim BH, Kim S, Schneekloth JS Jr, Caplen NJ.

RNA. 2019 Sep 11. pii: rna.072454.119. doi: 10.1261/rna.072454.119. [Epub ahead of print]

2.

Fusion transcripts: Unexploited vulnerabilities in cancer?

Neckles C, Sundara Rajan S, Caplen NJ.

Wiley Interdiscip Rev RNA. 2019 Aug 13:e1562. doi: 10.1002/wrna.1562. [Epub ahead of print] Review.

PMID:
31407506
3.

MAP kinase and autophagy pathways cooperate to maintain RAS mutant cancer cell survival.

Lee CS, Lee LC, Yuan TL, Chakka S, Fellmann C, Lowe SW, Caplen NJ, McCormick F, Luo J.

Proc Natl Acad Sci U S A. 2019 Feb 1. pii: 201817494. doi: 10.1073/pnas.1817494116. [Epub ahead of print]

4.

EWS-FLI1 reprograms the metabolism of Ewing sarcoma cells via positive regulation of glutamine import and serine-glycine biosynthesis.

Sen N, Cross AM, Lorenzi PL, Khan J, Gryder BE, Kim S, Caplen NJ.

Mol Carcinog. 2018 Oct;57(10):1342-1357. doi: 10.1002/mc.22849. Epub 2018 Jun 19.

5.

Functional Genomic Screening Reveals Splicing of the EWS-FLI1 Fusion Transcript as a Vulnerability in Ewing Sarcoma.

Grohar PJ, Kim S, Rangel Rivera GO, Sen N, Haddock S, Harlow ML, Maloney NK, Zhu J, O'Neill M, Jones TL, Huppi K, Grandin M, Gehlhaus K, Klumpp-Thomas CA, Buehler E, Helman LJ, Martin SE, Caplen NJ.

Cell Rep. 2016 Jan 26;14(3):598-610. doi: 10.1016/j.celrep.2015.12.063. Epub 2016 Jan 14.

6.

Targeting MPS1 Enhances Radiosensitization of Human Glioblastoma by Modulating DNA Repair Proteins.

Maachani UB, Kramp T, Hanson R, Zhao S, Celiku O, Shankavaram U, Colombo R, Caplen NJ, Camphausen K, Tandle A.

Mol Cancer Res. 2015 May;13(5):852-62. doi: 10.1158/1541-7786.MCR-14-0462-T. Epub 2015 Feb 26.

7.

Selective targeting of KRAS-mutant cells by miR-126 through repression of multiple genes essential for the survival of KRAS-mutant cells.

Hara T, Jones MF, Subramanian M, Li XL, Ou O, Zhu Y, Yang Y, Wakefield LM, Hussain SP, Gaedcke J, Ried T, Luo J, Caplen NJ, Lal A.

Oncotarget. 2014 Sep 15;5(17):7635-50.

8.

Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity.

Ou O, Huppi K, Chakka S, Gehlhaus K, Dubois W, Patel J, Chen J, Mackiewicz M, Jones TL, Pitt JJ, Martin SE, Goldsmith P, Simmons JK, Mock BA, Caplen NJ.

Cancer Lett. 2014 Nov 28;354(2):336-47. doi: 10.1016/j.canlet.2014.08.043. Epub 2014 Sep 1.

9.

Identification and validation of genes with expression patterns inverse to multiple metastasis suppressor genes in breast cancer cell lines.

Marino N, Collins JW, Shen C, Caplen NJ, Merchant AS, Gökmen-Polar Y, Goswami CP, Hoshino T, Qian Y, Sledge GW Jr, Steeg PS.

Clin Exp Metastasis. 2014 Oct;31(7):771-86. doi: 10.1007/s10585-014-9667-0. Epub 2014 Aug 3.

10.

Identification of novel molecular regulators of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in breast cancer cells by RNAi screening.

Garimella SV, Gehlhaus K, Dine JL, Pitt JJ, Grandin M, Chakka S, Nau MM, Caplen NJ, Lipkowitz S.

Breast Cancer Res. 2014 Apr 17;16(2):R41. doi: 10.1186/bcr3645.

11.

Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

Tandle AT, Kramp T, Kil WJ, Halthore A, Gehlhaus K, Shankavaram U, Tofilon PJ, Caplen NJ, Camphausen K.

Eur J Cancer. 2013 Sep;49(14):3020-8. doi: 10.1016/j.ejca.2013.05.013. Epub 2013 Jun 18.

12.

Genetic amplification of the NOTCH modulator LNX2 upregulates the WNT/β-catenin pathway in colorectal cancer.

Camps J, Pitt JJ, Emons G, Hummon AB, Case CM, Grade M, Jones TL, Nguyen QT, Ghadimi BM, Beissbarth T, Difilippantonio MJ, Caplen NJ, Ried T.

Cancer Res. 2013 Mar 15;73(6):2003-13. doi: 10.1158/0008-5472.CAN-12-3159. Epub 2013 Jan 14.

13.

Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer.

Bennett CN, Tomlinson CC, Michalowski AM, Chu IM, Luger D, Mittereder LR, Aprelikova O, Shou J, Piwinica-Worms H, Caplen NJ, Hollingshead MG, Green JE.

Breast Cancer Res. 2012 Jul 19;14(4):R109. doi: 10.1186/bcr3230.

14.

The 8q24 gene desert: an oasis of non-coding transcriptional activity.

Huppi K, Pitt JJ, Wahlberg BM, Caplen NJ.

Front Genet. 2012 Apr 30;3:69. doi: 10.3389/fgene.2012.00069. eCollection 2012.

15.

Systems-wide RNAi analysis of CASP8AP2/FLASH shows transcriptional deregulation of the replication-dependent histone genes and extensive effects on the transcriptome of colorectal cancer cells.

Hummon AB, Pitt JJ, Camps J, Emons G, Skube SB, Huppi K, Jones TL, Beissbarth T, Kramer F, Grade M, Difilippantonio MJ, Ried T, Caplen NJ.

Mol Cancer. 2012 Jan 4;11:1. doi: 10.1186/1476-4598-11-1.

16.

p53-Dependent induction of PVT1 and miR-1204.

Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C.

J Biol Chem. 2012 Jan 20;287(4):2509-19. doi: 10.1074/jbc.M111.322875. Epub 2011 Nov 22.

17.

RNAi screening identifies TAK1 as a potential target for the enhanced efficacy of topoisomerase inhibitors.

Martin SE, Wu ZH, Gehlhaus K, Jones TL, Zhang YW, Guha R, Miyamoto S, Pommier Y, Caplen NJ.

Curr Cancer Drug Targets. 2011 Oct;11(8):976-86.

18.

Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA.

Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ.

Breast Cancer Res Treat. 2011 Nov;130(2):663-79. doi: 10.1007/s10549-011-1690-0. Epub 2011 Aug 4.

19.

Genomic instability and mouse microRNAs.

Huppi K, Pitt J, Wahlberg B, Caplen NJ.

Toxicol Mech Methods. 2011 May;21(4):325-33. doi: 10.3109/15376516.2011.562759. Review.

20.

A genomic strategy for the functional validation of colorectal cancer genes identifies potential therapeutic targets.

Grade M, Hummon AB, Camps J, Emons G, Spitzner M, Gaedcke J, Hoermann P, Ebner R, Becker H, Difilippantonio MJ, Ghadimi BM, Beissbarth T, Caplen NJ, Ried T.

Int J Cancer. 2011 Mar 1;128(5):1069-79. doi: 10.1002/ijc.25453.

21.

Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome.

Murrow LM, Garimella SV, Jones TL, Caplen NJ, Lipkowitz S.

Breast Cancer Res Treat. 2010 Jul;122(2):347-57. doi: 10.1007/s10549-009-0571-2. Epub 2009 Oct 10.

22.

Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide].

Jobson AG, Lountos GT, Lorenzi PL, Llamas J, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH 2nd, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH, Pommier Y.

J Pharmacol Exp Ther. 2009 Dec;331(3):816-26. doi: 10.1124/jpet.109.154997. Epub 2009 Sep 9.

23.

Implication of checkpoint kinase-dependent up-regulation of ribonucleotide reductase R2 in DNA damage response.

Zhang YW, Jones TL, Martin SE, Caplen NJ, Pommier Y.

J Biol Chem. 2009 Jul 3;284(27):18085-95. doi: 10.1074/jbc.M109.003020. Epub 2009 May 5.

24.

Allele-specific silencing of the dominant disease allele in sialuria by RNA interference.

Klootwijk RD, Savelkoul PJ, Ciccone C, Manoli I, Caplen NJ, Krasnewich DM, Gahl WA, Huizing M.

FASEB J. 2008 Nov;22(11):3846-52. doi: 10.1096/fj.08-110890. Epub 2008 Jul 24.

25.

SpliceCenter: a suite of web-based bioinformatic applications for evaluating the impact of alternative splicing on RT-PCR, RNAi, microarray, and peptide-based studies.

Ryan MC, Zeeberg BR, Caplen NJ, Cleland JA, Kahn AB, Liu H, Weinstein JN.

BMC Bioinformatics. 2008 Jul 18;9:313. doi: 10.1186/1471-2105-9-313.

26.

Single-step doxorubicin-selected cancer cells overexpress the ABCG2 drug transporter through epigenetic changes.

Calcagno AM, Fostel JM, To KK, Salcido CD, Martin SE, Chewning KJ, Wu CP, Varticovski L, Bates SE, Caplen NJ, Ambudkar SV.

Br J Cancer. 2008 May 6;98(9):1515-24. doi: 10.1038/sj.bjc.6604334. Epub 2008 Apr 1.

27.

The identification of microRNAs in a genomically unstable region of human chromosome 8q24.

Huppi K, Volfovsky N, Runfola T, Jones TL, Mackiewicz M, Martin SE, Mushinski JF, Stephens R, Caplen NJ.

Mol Cancer Res. 2008 Feb;6(2):212-21. doi: 10.1158/1541-7786.MCR-07-0105.

28.

Pvt1-encoded microRNAs in oncogenesis.

Beck-Engeser GB, Lum AM, Huppi K, Caplen NJ, Wang BB, Wabl M.

Retrovirology. 2008 Jan 14;5:4. doi: 10.1186/1742-4690-5-4.

29.

Applications of RNA interference in mammalian systems.

Martin SE, Caplen NJ.

Annu Rev Genomics Hum Genet. 2007;8:81-108. Review.

PMID:
17477824
30.

Multiplexing siRNAs to compress RNAi-based screen size in human cells.

Martin SE, Jones TL, Thomas CL, Lorenzi PL, Nguyen DA, Runfola T, Gunsior M, Weinstein JN, Goldsmith PK, Lader E, Huppi K, Caplen NJ.

Nucleic Acids Res. 2007;35(8):e57. Epub 2007 Mar 28.

31.

MicroRNAs and genomic instability.

Huppi K, Volfovsky N, Mackiewicz M, Runfola T, Jones TL, Martin SE, Stephens R, Caplen NJ.

Semin Cancer Biol. 2007 Feb;17(1):65-73. Epub 2006 Oct 26. Review.

32.

Asparagine synthetase as a causal, predictive biomarker for L-asparaginase activity in ovarian cancer cells.

Lorenzi PL, Reinhold WC, Rudelius M, Gunsior M, Shankavaram U, Bussey KJ, Scherf U, Eichler GS, Martin SE, Chin K, Gray JW, Kohn EC, Horak ID, Von Hoff DD, Raffeld M, Goldsmith PK, Caplen NJ, Weinstein JN.

Mol Cancer Ther. 2006 Nov;5(11):2613-23. Epub 2006 Nov 6.

33.

Mismatched siRNAs downregulate mRNAs as a function of target site location.

Martin SE, Caplen NJ.

FEBS Lett. 2006 Jun 26;580(15):3694-8. Epub 2006 Jun 5.

34.

Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.

Ludwig JA, Szakács G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, Caplen NJ, Fales HM, Ambudkar SV, Weinstein JN, Gottesman MM.

Cancer Res. 2006 May 1;66(9):4808-15.

35.

Inefficient cationic lipid-mediated siRNA and antisense oligonucleotide transfer to airway epithelial cells in vivo.

Griesenbach U, Kitson C, Escudero Garcia S, Farley R, Singh C, Somerton L, Painter H, Smith RL, Gill DR, Hyde SC, Chow YH, Hu J, Gray M, Edbrooke M, Ogilvie V, MacGregor G, Scheule RK, Cheng SH, Caplen NJ, Alton EW.

Respir Res. 2006 Feb 15;7:26.

36.

Efficient delivery of RNA interference effectors via in vitro-packaged SV40 pseudovirions.

Kimchi-Sarfaty C, Brittain S, Garfield S, Caplen NJ, Tang Q, Gottesman MM.

Hum Gene Ther. 2005 Sep;16(9):1110-5.

37.

Kinase-independent functions for Itk in TCR-induced regulation of Vav and the actin cytoskeleton.

Dombroski D, Houghtling RA, Labno CM, Precht P, Takesono A, Caplen NJ, Billadeau DD, Wange RL, Burkhardt JK, Schwartzberg PL.

J Immunol. 2005 Feb 1;174(3):1385-92.

38.

Defining and assaying RNAi in mammalian cells.

Huppi K, Martin SE, Caplen NJ.

Mol Cell. 2005 Jan 7;17(1):1-10. Review.

39.
40.

RNAi quashes polyQ.

Caplen NJ.

Nat Med. 2004 Aug;10(8):775-6. No abstract available.

PMID:
15286770
41.

In situ generation of pseudotyped retroviral progeny by adenovirus-mediated transduction of tumor cells enhances the killing effect of HSV-tk suicide gene therapy in vitro and in vivo.

Okada T, Caplen NJ, Ramsey WJ, Onodera M, Shimazaki K, Nomoto T, Ajalli R, Wildner O, Morris J, Kume A, Hamada H, Blaese RM, Ozawa K.

J Gene Med. 2004 Mar;6(3):288-99.

PMID:
15026990
42.

Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells.

Scacheri PC, Rozenblatt-Rosen O, Caplen NJ, Wolfsberg TG, Umayam L, Lee JC, Hughes CM, Shanmugam KS, Bhattacharjee A, Meyerson M, Collins FS.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1892-7. Epub 2004 Feb 9.

43.

Short interfering RNA (siRNA)-mediated RNA interference (RNAi) in human cells.

Caplen NJ, Mousses S.

Ann N Y Acad Sci. 2003 Dec;1002:56-62. Review.

PMID:
14751822
44.

RNAi microarray analysis in cultured mammalian cells.

Mousses S, Caplen NJ, Cornelison R, Weaver D, Basik M, Hautaniemi S, Elkahloun AG, Lotufo RA, Choudary A, Dougherty ER, Suh E, Kallioniemi O.

Genome Res. 2003 Oct;13(10):2341-7.

45.

RNAi as a gene therapy approach.

Caplen NJ.

Expert Opin Biol Ther. 2003 Jul;3(4):575-86. Review.

PMID:
12831363
46.
47.

A new approach to the inhibition of gene expression.

Caplen NJ.

Trends Biotechnol. 2002 Feb;20(2):49-51. No abstract available.

PMID:
11814589
48.

Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference.

Caplen NJ, Taylor JP, Statham VS, Tanaka F, Fire A, Morgan RA.

Hum Mol Genet. 2002 Jan 15;11(2):175-84.

PMID:
11809726
49.

Cystic fibrosis gene therapy trials and tribulations.

Caplen NJ.

Trends Mol Med. 2001 Nov;7(11):488. No abstract available.

PMID:
11689316
50.

Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems.

Caplen NJ, Parrish S, Imani F, Fire A, Morgan RA.

Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9742-7. Epub 2001 Jul 31.

Supplemental Content

Loading ...
Support Center